Authored By: Sarah
11 Jul 2024

 Gastric Cancer Drugs Market Size to grow by USD 19489.6 million between 2024-2028

According to a research report “ Gastric Cancer Drugs Market” by Route Of Administration (Injectable, Oral) Distribution Channel (Offline, Online) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 19489.6 million, at a CAGR of  18.52% during the forecast period. In the business realm of healthcare, the delayed diagnosis of gastric cancer is a significant challenge due to the subtlety of its symptoms and limited public awareness. This results in a high morbidity rate for the disease. To mitigate this issue, organizations like The Life Raft Group are spearheading initiatives to increase awareness and education at both regional and global levels. By providing vital information, educating medical professionals, and supporting innovative research, this non-profit organization aims to reduce the time from symptom onset to diagnosis and from diagnosis to treatment, ultimately improving patient outcomes in the gastric cancer drugs market.

Browse market data tables, figures, and in-depth TOC on “Gastric Cancer Drugs Market” by Route Of Administration (Injectable, Oral) Distribution Channel (Offline, Online) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Route Of Administration, the Injectable segment is projected to dominate the market size in 2024

The offline segment, which includes the distribution of gastric cancer drugs through hospital pharmacies and specialty and retail pharmacies, remains a significant player in the market. Although online distribution channels have gained traction, the convenience and accessibility of offline channels continue to appeal to consumers. Patients often prefer purchasing gastric cancer medications from hospital pharmacies and specialty and retail pharmacies due to the immediate availability and direct consultations with pharmacists. This preference benefits both established and emerging pharmaceutical companies, enabling them to expand their consumer reach within the offline market.

By Distribution Channel, Offline  segment is expected to hold the largest market size for the year 2024

In the realm of gastric cancer treatments, injectable drugs have emerged as a preferred choice for several pharmaceutical companies. The injectable route, which involves administering drugs through a hypodermic needle, is widely used for biologics due to their large molecular size and susceptibility to degradation in the gastrointestinal tract. Notably, Merck's KEYTRUDA, an injectable drug, recently secured a sBLA submission with the US FDA for gastric cancer indication, underscoring the market's growing focus on this drug delivery method. The pipeline is brimming with innovative injectable drugs, with several vendors vying to bring novel treatments to market.

North America is forecasted to hold the largest market size by region in 2024

The Gastric Cancer Drugs Market represents a significant business opportunity for pharmaceutical companies, driven by the rising prevalence of gastric cancer worldwide. Key players in this market are focusing on developing innovative therapies to address the unmet medical needs of patients. These include targeted therapies, immunotherapies, and chemotherapies. Market growth is also fueled by increasing government funding for cancer research and rising healthcare expenditures. Despite challenges, such as stringent regulatory requirements and high development costs, the future of the Gastric Cancer Drugs Market looks promising.

The Gastric Cancer Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • AROG Pharmaceuticals INC.
  • AstraZeneca Plc
  • Bayer AG
  • Biocon Ltd.
  • Blueprint Medicines Corp.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Celltrion Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Merck KGaA
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Samsung Biologics Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Zydus Lifesciences Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Gastric cancer is a severe condition that can cause various symptoms such as weight loss, vomiting, stomach pain, bloating, and fatigue. Biomarkers, including family history and specific proteins, can help diagnose this disease in its early stages. Pharmaceutical giants like Samsung Bioepis, Celltrion/Teva, Biocon/Mylan, and AstraZeneca have introduced several drugs to treat gastric cancer. These include biosimilars of Herceptin, Ogivri, and Herzuma, as well as PD-1 inhibitors like Opdivo, Cyramza, and Keytruda. Trastuzumab deruxtecan from AstraZeneca is another promising drug for treating advanced gastric cancer. Gastric Neuroendocrine Tumors and Gastrointestinal Stromal Tumor also require specific treatments. Symptoms like vomiting, stomach pain, and weight loss can significantly impact patients' quality of life. Early diagnosis and appropriate treatment are crucial for managing gastric carcinoma cases effectively.

Market Research Overview

Gastric cancer is a type of malignancy that affects the stomach lining. Symptoms include weight loss, vomiting, stomach pain, bloating, and fatigue. Risk factors include family history, genetic modification, smoking, gastrointestinal reflux disease, and obesity. The global gastric cancer market for oral drugs is expanding due to the development of targeted therapy, immunotherapy, and chemotherapy. Platinum-containing chemotherapy drugs like Qinlock (dostarlimab) and Stivarga (regorafenib) are used for treating advanced gastrointestinal stromal tumors (GIST). Gleevec (imatinib) and Ayvakit (avapritinib) are HER2 antagonists for treating GIST. Enhertu (fam-trastuzumab deruxtecan) and Herceptin (trastuzumab) are HER2 antagonists for treating HER2-positive gastric adenocarcinoma. Biosimilars like Trazimera, Ontruzant, Ogivri, and Herzuma are gaining popularity in hospital and specialty pharmacies. Key players in the market include Bristol Myers Squibb, Daiichi Sankyo Company, Oncoral, and Samsung Bioepis. Targeted therapy and immunotherapy are also used for treating gastroesophageal junction cancer. Opdivo (nivolumab) and Cyramza (ramucirumab) are PD-1 inhibitors for treating advanced gastric neuroendocrine tumors. Fluorouracil, Capecitabine, and Lonsurf are VEGFR antagonists used for treating advanced gastric adenocarcinoma. Avelumab, Keytruda, and Trastuzumab deruxtecan are also used for treating various types of gastric cancers. The market is expected to grow due to the increasing number of gastric carcinoma cases and the development of new drugs.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio